| The metabolic basis of kidney cancer WM Linehan, LS Schmidt, DR Crooks, D Wei, R Srinivasan, M Lang, ... Cancer Discovery 9 (8), 1006-1021, 2019 | 220 | 2019 |
| A chemoproteomic portrait of the oncometabolite fumarate RA Kulkarni, DW Bak, D Wei, SE Bergholtz, CA Briney, JH Shrimp, ... Nature chemical biology 15 (4), 391-400, 2019 | 97 | 2019 |
| Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma P Msaouel, AL Hong, EA Mullen, MB Atkins, CL Walker, CH Lee, ... Clinical genitourinary cancer 17 (1), 1-6, 2019 | 72 | 2019 |
| SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their … Y Kuwahara, D Wei, J Durand, BE Weissman Molecular Cancer Research 11 (3), 251-260, 2013 | 47 | 2013 |
| Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers C Sourbier, PJ Liao, CJ Ricketts, D Wei, Y Yang, SM Baranes, BK Gibbs, ... Oncotarget 9 (12), 10723, 2018 | 42 | 2018 |
| SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development D Wei, D Goldfarb, S Song, C Cannon, F Yan, D Sakellariou-Thompson, ... Molecular Cancer Research 12 (11), 1574-1585, 2014 | 42 | 2014 |
| Loss of SWI/SNF chromatin remodeling alters NRF2 signaling in non–small cell lung carcinoma S Song, V Nguyen, T Schrank, K Mulvaney, V Walter, D Wei, T Orvis, ... Molecular Cancer Research 18 (12), 1777-1788, 2020 | 32 | 2020 |
| The metabolic basis of kidney cancer. Cancer Discov. 2019; 9: 1006–1021. doi: 10.1158/2159-8290 WM Linehan, LS Schmidt, DR Crooks, D Wei, R Srinivasan, M Lang, ... CD-18-1354.[Abstract][CrossRef][Google Scholar], 0 | 29 | |
| Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276) Y Yang, CD Vocke, CJ Ricketts, D Wei, HM Padilla‐Nash, M Lang, ... Genes, Chromosomes and Cancer 56 (10), 719-729, 2017 | 22 | 2017 |
| A Combinatorial Strategy for Targeting BRAFV600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib) C Ghosh, S Kumar, Y Kushchayeva, K Gaskins, M Boufraqech, D Wei, ... Clinical Cancer Research 26 (8), 2022-2036, 2020 | 18 | 2020 |
| Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion EC Kauffman, M Lang, S Rais-Bahrami, GN Gupta, D Wei, Y Yang, ... BMC cancer 19, 1-12, 2019 | 18 | 2019 |
| Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines Y Yang, CJ Ricketts, CD Vocke, JK Killian, HM Padilla‐Nash, M Lang, ... Genes, Chromosomes and Cancer 60 (6), 434-446, 2021 | 13 | 2021 |
| Mithramycin A enhances tumor sensitivity to mitotic catastrophe resulting from DNA damage BT Scroggins, J Burkeen, AO White, EJ Chung, D Wei, SI Chung, LF Valle, ... International Journal of Radiation Oncology* Biology* Physics 100 (2), 344-352, 2018 | 12 | 2018 |
| Proteasome inhibition disrupts the metabolism of fumarate hydratase-deficient tumors by downregulating p62 and c-Myc C Sourbier, CJ Ricketts, PJ Liao, S Matsumoto, D Wei, M Lang, R Railkar, ... Scientific Reports 9 (1), 18409, 2019 | 11 | 2019 |
| Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments D Wei, Y Yang, CJ Ricketts, CD Vocke, MW Ball, C Sourbier, D Wangsa, ... Genes, Chromosomes and Cancer 59 (8), 472-483, 2020 | 8 | 2020 |
| LOX is a novel mitotic spindle-associated protein essential for mitosis M Boufraqech, D Wei, U Weyemi, L Zhang, M Quezado, P Kalab, ... Oncotarget 7 (20), 29023, 2016 | 8 | 2016 |
| Genetics and Genomics of Malignant Rhabdoid Tumours D Wei, BE Weissman eLS, 2014 | 7 | 2014 |
| The metabolic basis of kidney cancer. Cancer Discov. 2019; 9 (8): 1006–21 WM Linehan, LS Schmidt, DR Crooks, D Wei, R Srinivasan, M Lang, ... Epub 2019/05/16. https://doi. org/10.1158/2159-8290. CD-18-1354 PMID: 31088840, 0 | 7 | |
| High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma M Lang, LS Schmidt, KM Wilson, CJ Ricketts, C Sourbier, CD Vocke, ... Journal of Experimental & Clinical Cancer Research 42 (1), 99, 2023 | 5 | 2023 |
| The metabolic basis of kidney cancer. Cancer Discov. 9, 1006–1021 WM Linehan, LS Schmidt, DR Crooks, D Wei, R Srinivasan, M Lang, ... | 5 | 2019 |
W M LinehanNational Cancer Institute在 nih.gov 的电子邮件经过验证
